The Spanish Competition Authority fines the maker of an orphan medicine to treat a rare metabolic disorder €10.25 million for imposing excessive prices (Leadiant)

On 14/11/2022, the Spanish Competition Authority (CNMC) imposed a fine of EUR 10.25 million on Leadiant because that firm was found to have abused its dominant position by applying excessive prices for chenodeoxycholic acid, an orphan medicine indicated for the treatment of

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)
  • Van Bael & Bellis (Brussels)

Quotation

Catherine Longeval, Peter L'Ecluse, Michael Clancy, Koen T'Syen, The Spanish Competition Authority fines the maker of an orphan medicine to treat a rare metabolic disorder €10.25 million for imposing excessive prices (Leadiant), 14 November 2022, e-Competitions November 2022 - II, Art. N° 109679

Visites 641

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues